Pipeline

Scientific KOL

A unique international network of Key Opinion Leaders in neurology with strong emphasis on the Parkinson’s disease

Dr. Jean-Christophe Corvol

More than 80 publications in International journals, Researches focused on Drug development, Biomarkers & pharmacogenetics of Parkinson’s Disease. Professor in Neuro-pharmacology & Head in Neurosciences Clinical Research Center – Pitié-Salpêtrière Hospital (APHP, INSERM, CIC-1422) & principal investigator in the research team of Alexis Brice (CR-ICM), Post-doc in the field of Transcriptomic biomarkers Molecular Neurogenetics Laboratory UCSF San Francisco, Member of the French Society of Pharmacology, the French Society of Neurology, and the Movement Disorder Society, the Scientific Board of INSERM for Neurosciences, the French Association for Parkinson’s Disease, the French Foundation for Brain Research, External expert for several grant applications & international journals, Associate editor for the Movement Disorder Journal. M.D in Neurology, Ph.D. in Neurosciences

Olivier Rascol

More than 400 publications in International journals, Activities focused on Movement disorders & Neuro-pharmacology, Drug development for Parkinson’s disease and functional Neuroimaging.
Professor of Clinical Pharmacology – Toulouse University Hospital, Toulouse European Space Clinic a Research Group on Motricity (Research Unit INSERM U825) & Coordinator – French Reference Center for Multiple System Atrophy (Atypical Parkinsonism), Chair – National network of the 56 French Clinical Investigation Centers & of the NS-Park Neurosciences Network of the French CIC, Coordinator – National French Clinical Research Infrastructure Network F-CRIN, Involved in several marketed antiparkinsonian medications, Board Member of Evidence-Based Medicine MDS Task Force (All antiparkinsonian treatments), Involved in the process of editing French (HAS) & European (EFNS / MDS-ES) guidelines (Treatment of Parkinson’s disease)
Member of several French & American neurological and pharmacological companies – WFN Research Committee on Parkinsonism & Related Disorders, Chair of the European Section of the Movement Disorders Society, Associate-editor – Journal Fundamental & Clinical Pharmacology; Member of the editorial board – Lancet Neurology, European Journal of Neurology, the Journal of Neural Transmission, Evidence Medicine
M.D in Neurology, Ph.D. in Neurosciences

Laura BOSSI REGNIER

More than 120 scientific publications & six books, Activities focused on Movement disorders & Neurodegeneration
Senior strategic consultant to companies for the development of new therapeutics of neurological & psychiatric disorders, Involved in research projects in neurosciences
Chief Medical Officer & Director of Preclinical & Clinical – Pharnext & Faust Pharmaceuticals, Chief Executive Officer & founder – Elistem & Physis, Vice President Director – C.N.S. Therapeutic Area worldwide SANOFI Recherche, Chief Executive Officer – Fidia France , Director – International CNS Clinical Development, LERS & Synthélabo
M.D in Neurology, Awarded as « Chevalier de la légion d’honneur »

Pr. Christopher Goetz

Major interest focused on Movement disorders, Parkinson’s disease, Gilles de la Tourette’s syndrome, Huntington’s disease and dystonia. Director on Movement Disorders at Neurological Sciences Dep. – Parkinson’s Disease Foundation Rush University Medical Center, Scientific Advisory Board Member – National Tourette Syndrome Association & Dystonia Medical Research Foundation
Director of the Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease – dyskinesias & behavioral aspects of Parkinson’s disease, hallucinations, cognitive decline & depression, Extensive research & work – Unified Dyskinesia Rating Scale , Rush Dyskinesia Scale
M.D in Neurology

Dr.Fabrizio Stocchi

Research experience centered on Neuropharmacology in the field of movement disorders and neurodegenerative diseases. Honorary Consultant & Professor/Neuromed & University of Rome “La Sapienza“, Scientific Director/Institute for Parkinson’s disease research “Antonio Benedetti” Vicenza , Consultant for the Neuro Pharmacological/Research Program Neuromed/I.R.C.C.S Pozzilli
Scientific Advisory Board & Clinical Advisory Board Member – Newron Pharmaceuticals SpA, Clinical Advisory Board Member/Cynapsus Therapeutics Inc. M.D – University of l’Aquila , Ph.D. in Neurology – University of Catania